Ann Lab Med.  2024 Mar;44(2):119-121. 10.3343/alm.2023.0391.

Next-Generation Sequencing-Based Molecular Profiling Using Cell-Free DNA: A Valuable Tool for the Diagnostic and Prognostic Evaluation of Patients With Gastric Cancer

• Jang MA

• KMID: 2553373
• DOI: http://doi.org/10.3343/alm.2023.0391

Keyword

Biomarkers; Cell-free nucleic acids; Disease-free survival; Genomics; High-throughput nucleotide sequencing; Liquid biopsy; Prognosis; Stomach neoplasms

Reference

1. International Agency for Research on Cancer, WHO. Global Cancer Observatory: Cancer Today. https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf. Updated on Sep 2023. Lyon, France: International Agency for Research on Cancer.

2. National Comprehensive Cancer Network. Gastric Cancer: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Version 2.2023. August 29, 2023.

3. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. 2020; Gastric cancer. Lancet. 396:635–48. DOI: 10.1016/S0140-6736(20)31288-5. PMID: 32861308.

4. Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. 2022; Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 33:1005–20. DOI: 10.1016/j.annonc.2022.07.004. PMID: 35914639.

5. Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, et al. 2019; Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 37:3392–400. DOI: 10.1200/JCO.19.01124. PMID: 31513484.

6. Telekes A, Horváth A. 2022; The role of cell-free DNA in cancer treatment decision making. Cancers (Basel). 14:6115. DOI: 10.3390/cancers14246115. PMID: 36551600. PMCID: PMC9776613.

7. Zhong Y, Xu F, Wu J, Schubert J, Li MM. 2021; Application of next generation sequencing in laboratory medicine. Ann Lab Med. 41:25–43. DOI: 10.3343/alm.2021.41.1.25. PMID: 32829577. PMCID: PMC7443516.

8. Huffman BM, Aushev VN, Budde GL, Chao J, Dayyani F, Hanna D, et al. 2022; Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers. JCO Precis Oncol. 6:e2200420. DOI: 10.1200/PO.22.00420. PMID: 36480779. PMCID: PMC10530958.

9. Grizzi G, Salati M, Bonomi M, Ratti M, Holladay L, De Grandis MC, et al. 2023; Circulating tumor DNA in gastric adenocarcinoma: future clinical applications and perspectives. Int J Mol Sci. 24:9421. DOI: 10.3390/ijms24119421. PMID: 37298371. PMCID: PMC10254023.

10. Lengyel CG, Hussain S, Trapani D, El Bairi K, Altuna SC, Seeber A, et al. The emerging role of liquid biopsy in gastric cancer. J Clin Med. 2021; 10:DOI: 10.3390/jcm10102108. PMID: 34068319. PMCID: PMC8153353.

11. Kim B, Kim Y, Cho J, Lee K. 2023; Identification of potential genomic alterations using pan-cancer cell-free DNA next-generation sequencing in patients with gastric cancer. Ann Lab Med. 44:164–73. DOI: 10.3343/alm.2023.0187. PMID: 37903652.

12. Cho SM, Lee HS, Jeon S, Kim Y, Kong SY, Lee JK, et al. 2023; Cost-effectiveness analysis of three diagnostic strategies for the detection of EGFR mutation in advanced non-small cell lung cancer. Ann Lab Med. 43:605–13. DOI: 10.3343/alm.2023.43.6.605. PMID: 37387493. PMCID: PMC10345179.

13. Shin S, Woo HI, Kim JW, M D YK, Lee KA. 2022; Clinical practice guidelines for pre-analytical procedures of plasma epidermal growth factor receptor variant testing. Ann Lab Med. 42:141–9. DOI: 10.3343/alm.2022.42.2.141. PMID: 34635607. PMCID: PMC8548242.